Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Nurix Therapeutics Inc (NASDAQ: NRIX) closed at $9.08 down -3.40% from its previous closing price of $9.4. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 0.63 million shares were traded. NRIX stock price reached its highest trading level at $9.69 during the session, while it also had its lowest trading level at $8.9364.
Ratios:
For a deeper understanding of Nurix Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.82 and its Current Ratio is at 6.82. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 17, 2025, initiated with a Market Perform rating and assigned the stock a target price of $16.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $35.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $35.BMO Capital Markets initiated its Outperform rating on December 06, 2024, with a $35 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 01 ’25 when van Houte Hans sold 5,402 shares for $11.03 per share. The transaction valued at 59,598 led to the insider holds 35,512 shares of the business.
JOHANNES VAN HOUTE bought 5,402 shares of NRIX for $60,827 on Aug 01 ’25. On Jul 30 ’25, another insider, van Houte Hans, who serves as the Chief Financial Officer of the company, sold 4,304 shares for $12.01 each. As a result, the insider received 51,695 and left with 40,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NRIX now has a Market Capitalization of 694160128 and an Enterprise Value of 260310144. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.85 while its Price-to-Book (P/B) ratio in mrq is 1.55. Its current Enterprise Value per Revenue stands at 2.945 whereas that against EBITDA is -1.171.
Stock Price History:
The Beta on a monthly basis for NRIX is 2.27, which has changed by -0.590991 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, NRIX has reached a high of $29.56, while it has fallen to a 52-week low of $8.18. The 50-Day Moving Average of the stock is -7.09%, while the 200-Day Moving Average is calculated to be -30.02%.
Shares Statistics:
For the past three months, NRIX has traded an average of 944.14K shares per day and 1377550 over the past ten days. A total of 76.43M shares are outstanding, with a floating share count of 74.92M. Insiders hold about 1.99% of the company’s shares, while institutions hold 115.92% stake in the company. Shares short for NRIX as of 1757894400 were 13045894 with a Short Ratio of 13.82, compared to 1755216000 on 12876254. Therefore, it implies a Short% of Shares Outstanding of 13045894 and a Short% of Float of 20.05.
Earnings Estimates
Nurix Therapeutics Inc (NRIX) is presently subject to a detailed evaluation by 15.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.76 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$2.72 and -$3.24 for the fiscal current year, implying an average EPS of -$2.96. EPS for the following year is -$3.65, with 15.0 analysts recommending between -$1.97 and -$4.51.
Revenue Estimates
A total of 17 analysts have provided revenue estimates for NRIX’s current fiscal year. The highest revenue estimate was $112.96M, while the lowest revenue estimate was $59.97M, resulting in an average revenue estimate of $91.75M. In the same quarter a year ago, actual revenue was $54.55M
